Sage Therapeutics, Inc. (SAGE) financial statements (2020 and earlier)

Company profile

Business Address 215 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,008923519397187128
Cash and cash equivalents127191306169187128
Short-term investments882732213229  
Deferred costs    0 
Other undisclosed current assets27226521
Total current assets:1,035945525403188129
Noncurrent Assets
Operating lease, right-of-use asset34
Property, plant and equipment964100
Restricted cash and investments221100
Other noncurrent assets4     
Other undisclosed noncurrent assets    01
Total noncurrent assets:4985211
TOTAL ASSETS:1,084953530405189130
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities102865235158
Accounts payable153491352
Accrued liabilities87524322105
Employee-related liabilities     1
Debt10     
Deferred tax liabilities    1
Other undisclosed current liabilities     (1)
Total current liabilities:112865235158
Noncurrent Liabilities
Long-term debt and lease obligation27     
Operating lease, liability27
Liabilities, other than long-term debt143100
Other liabilities143100
Total noncurrent liabilities:2743100
Total liabilities:139905436158
Stockholders' equity
Stockholders' equity attributable to parent945863475369174122
Common stock000000
Treasury stock, value(0)(0)(0)(0)  
Additional paid in capital2,5871,8271,066689335189
Accumulated other comprehensive income (loss)1(1)(0)(0)  
Accumulated deficit(1,644)(963)(590)(320)(161)(67)
Total stockholders' equity:945863475369174122
TOTAL LIABILITIES AND EQUITY:1,084953530405189130

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:790    
Operating expenses(715)(484)(273)(160)(95)(34)
Operating loss:(708)(393)(273)(160)(95)(34)
Nonoperating income (expense)710(0)(0)(0)(0)
Investment income, nonoperating710    
Other nonoperating income (expense)00(0)(0)(0)(0)
Loss before gain (loss) on sale of properties:(701)(383)(273)(160)(95)(34)
Other undisclosed net income2110    
Net loss:(680)(373)(273)(160)(95)(34)
Other undisclosed net income attributable to parent  3100
Net loss attributable to parent:(680)(373)(270)(159)(94)(34)
Preferred stock dividends and other adjustments     (2)
Net loss available to common stockholders, diluted:(680)(373)(270)(159)(94)(36)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(680)(373)(273)(160)(95)(34)
Other comprehensive income (loss)2(0)0(0)  
Comprehensive loss:(678)(373)(273)(160)(95)(34)
Other undisclosed comprehensive income, net of tax, attributable to parent  31  
Comprehensive loss, net of tax, attributable to parent:(678)(373)(270)(159)(95)(34)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: